Published in Blood Weekly, February 16th, 2006
"Meisoindigo, an active compound of a Chinese anti-leukemia medicine, has been effectively used in the treatment of CML. Increasing evidences have demonstrated that angiogenesis is an important pathobiologic feature of CML," scientists writing in the journal Leukemia Research report.
"The antiangiogenesis effect of meisoindigo on CML is unknown. In this study, we determined the effects of meisoindigo on the apoptosis, adherence, and differentiation of endothelial cells as well as the secretion of vascular endothelial growth factor (VEGF) by CML cells," wrote...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.